ERK Cancer Research Results

ERK, ERK signaling: Click to Expand ⟱
Source:
Type:
MAPK3 (ERK1)
ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop.
The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior

EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes.
Scientific Papers found: Click to Expand⟱
2443- RES,    Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review
- Review, Var, NA
*antiOx↑, *ROS↓, *PTEN↑, *Akt↓, *Catalase↑, *SOD↑, *ERK↓, *GSH↑, *AMPK↑, *FOXO1↝, *RNS↓, *Catalase↑, *cardioP↑, *PI3K↑, *eNOS↑, hepatoP↑,
2440- RES,    Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway
- in-vitro, Lung, H460 - in-vivo, Lung, NA - in-vitro, Lung, H1650 - in-vitro, Lung, HCC827
AntiTum↑, Glycolysis↓, HK2↓, EGFR↓, Akt↓, ERK↓, GlucoseCon↓, lactateProd↓, TumCG↓, Ki-67↓,
3084- RES,    Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling
- in-vitro, BC, MCF7 - in-vitro, BC, T47D
TumCP↓, EZH2↓, p‑ERK↓,
3094- RES,    Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
CSCs↓, tumCV↓, FASN↑, BNIP3↑, *cardioP↑, *antiOx↑, NF-kB↓, COX2↓, MMP9↓, IGF-1↓, ERK↓, lipid-P↓, CD24↓,
1745- RosA,    Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications
- Review, Var, NA - Review, AD, NA
ChemoSideEff↓, ChemoSen↑, antiOx↑, MMP2↓, MMP9↓, p‑AMPK↑, DNMTs↓, tumCV↓, COX2↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, Casp3↑, Casp9↓, ROS↓, GSH↑, ERK↓, Akt↓, ROS↓, NF-kB↓, p‑IκB↓, p50↓, p65↓, neuroP↑, Dose↝,
1744- RosA,    Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity
- Review, Var, NA
chemoR↓, ChemoSideEff↓, RadioS↑, ROS↓, ChemoSen↑, BioAv↑, Half-Life↝, antiOx↑, ROS↑, Fenton↑, DNAdam↑, Apoptosis↑, CSCs↓, HH↓, Bax:Bcl2↑, MDR1↓, P-gp↓, eff↑, eff↑, FOXO4↑, *eff↑, *ROS↓, *JNK↓, *ERK↓, *GSH↑, *H2O2↑, *MDA↓, *SOD↑, *HO-1↑, *CardioT↓, selectivity↑,
3016- RosA,    Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling
- in-vitro, HNSCC, UM-SCC-6 - in-vitro, HNSCC, UM-SCC-10B
chemoP↓, EGF↓, tumCV↓, TumCMig↓, ROS↓, PI3K↓, Akt↓, ERK↓, antiOx↑, p‑EGFR↓,
4217- Sage,  RosA,  Aroma,    Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender
- Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *ERK↑, *CREB↑, *BDNF↑, *Aβ↑, *AChE↓, *memory↑, *cognitive↑,
1210- SANG,    Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer
- in-vitro, BC, NA
EphB4↓, Hif1a↓, STAT3↓, MAPK↓, ERK↓,
1090- SANG,    Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.
- in-vitro, BC, MCF7
MMP9↓, COX2↓, PGE2↓, NF-kB↓, AP-1↓, p‑Akt↓, p‑ERK↓, HO-1↑,
4198- SFN,    Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways
- vitro+vivo, AD, NA
*TrkB↑, *CREB↑, CaMKII ↑, *ERK↑, *ac‑H3↑, *ac‑H4↑, *HDAC↓, *HDAC2↓, *BDNF↑,
3189- SFN,    Sulforaphane Inhibits TNF-α-Induced Adhesion Molecule Expression Through the Rho A/ROCK/NF-κB Signaling Pathway
- in-vitro, Nor, ECV304
*ICAM-1↓, *IL1β↓, *IL6↓, *IL8↓, *p‑IKKα↓, *Rho↓, *ROCK1↓, *ERK↓, *Inflam↓,
3656- SFN,    Chronic diseases, inflammation, and spices: how are they linked?
- Review, AD, NA
*AntiCan↑, *cardioP↑, *NRF2↑, *Inflam↓, *NF-kB↓, *STAT3↓, *ERK↓, *MAPK↓, AP-1↑, Bcl-2↓, Casp3↑, Casp9↑,
963- SFN,    Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells
- in-vitro, CRC, HCT116 - in-vitro, GC, AGS
Hif1a↓, VEGF↓, angioG↓, Akt∅, ERK∅,
1498- SFN,    Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells
- in-vitro, CRC, HCT116 - in-vitro, Nor, NCM460
selectivity↑, TumCCA↑, Apoptosis↑, *p‑ERK↑, cMYB↓, selectivity↑, selectivity↑,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1452- SFN,    Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells
- in-vitro, GC, AGS
MMP9↓, p38↓, ERK↓, AP-1↓, ROS↓, NF-kB↓, TumCI↓, MMP9↓, HDAC↓, Glycolysis↓, Hif1a↓, *memory↑, *cognitive↑,
1474- SFN,    Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway
- in-vitro, Colon, SW480
TumCG↓, Apoptosis↑, MMP↓, Bax:Bcl2↑, Casp3↑, Casp7↑, Casp9↑, ROS↑, e-ERK↑, p38↑, P53∅, eff↓, ChemoSen↑,
1508- SFN,    Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment
- Review, Var, NA
*BioAv↑, HDAC↓, TumCCA↓, eff↓, Wnt↓, β-catenin/ZEB1↓, Casp12?, Bcl-2↓, cl‑PARP↑, Bax:Bcl2↑, IAP1↓, Casp3↑, Casp9↑, Telomerase↓, hTERT/TERT↓, ROS?, DNMTs↓, angioG↓, VEGF↓, Hif1a↓, cMYB↓, MMP1↓, MMP2↓, MMP9↓, ERK↑, E-cadherin↑, CD44↓, MMP2↓, eff↑, IL2↑, IFN-γ↑, IL1β↓, IL6↓, TNF-α↓, NF-kB↓, ERK↓, NRF2↑, RadioS↑, ChemoSideEff↓,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
3319- SIL,    Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3295- SIL,    Hepatoprotective effect of silymarin
- Review, NA, NA
*hepatoP↑, *ROS↓, *GSH↑, *BioAv↝, ERK↓, NF-kB↓, STAT3↓, COX2↓, Inflam↓, IronCh↑, lipid-P↓, ALAT↓, AST↓, TNF-α↓, *α-SMA↓, *SOD↑,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2211- SK,    Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways
- in-vivo, ostP, NA
*BMD↑, *p‑NF-kB↓, *p‑p50↓, *p‑p65↓, *p‑ERK↓, *p‑cJun↓, *p‑p38↓,
2231- SK,    Shikonin Exerts Cytotoxic Effects in Human Colon Cancers by Inducing Apoptotic Cell Death via the Endoplasmic Reticulum and Mitochondria-Mediated Pathways
- in-vitro, CRC, SNU-407
Apoptosis↑, ER Stress↑, PERK↑, eIF2α↑, CHOP↑, mt-Ca+2↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, ERK↑, JNK↑, p38↓,
2188- SK,    Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
- Review, Var, NA
ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
3042- SK,    The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways
- in-vivo, Nor, NA
*TNF-α↓, *IL1β↓, *IL6↓, *IFN-γ↓, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *JNK↓, *ERK↓, *p38↓, *NF-kB↓, *p‑IKKα↓, *SOD↑, *GSH↑, *HO-1↑, *NRF2↑, *hepatoP↑,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
2469- SK,    Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
- in-vitro, Lung, H1975
Apoptosis↑, Pyro↑, Casp↑, cl‑PARP↑, GSDME↑, ROS↑, COX2↓, PDK1↓, Akt↓, ERK↓, eff↓, eff↓, eff↑,
1281- SK,    Enhancement of NK cells proliferation and function by Shikonin
- in-vivo, Colon, Caco-2
Perforin↑, GranB↑, p‑ERK↑, p‑Akt↑, NK cell↑, eff↝,
1312- SK,    Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells
- in-vitro, OS, 143B
ROS↑, p‑ERK↑, Bcl-2↓, cl‑PARP↑, Apoptosis↑, TumCCA↑, Bcl-2↑, proCasp3↓,
1133- SM,    Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia
- in-vitro, Nor, HPAECs
*ROS↓, *p‑Smad1↑, *p‑SMAD5↑, *SMAD2↓, *SMAD3↓, *p‑ERK↓, *p‑Cofilin↓,
1195- SM,    Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116
T-Cell↑, TumCP∅, IL4↑, IL6↑, IFN-γ↑, TLR4↑, TLR1↑, TLR2↑, p‑JNK↑, p‑ERK↑, IKKα↑,
5333- TFdiG,    Theaflavin-3,3′-Digallate Plays a ROS-Mediated Dual Role in Ferroptosis and Apoptosis via the MAPK Pathway in Human Osteosarcoma Cell Lines and Xenografts
- vitro+vivo, OS, MG63
tumCV↓, TumCP↓, TumCCA↑, Iron↑, ROS↑, GSH↓, Fenton↑, Ferroptosis↑, Apoptosis↑, MAPK↑, ERK↑, JNK↑, p38↑, TumCG↓, Dose↝, FTH1↓, GPx4↓,
139- Tomatine,  CUR,    Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
- in-vitro, Pca, PC3
NF-kB↓, Bcl-2↓, p‑Akt↓, p‑ERK↓, TumCG↓, Apoptosis↑, PCNA↓, BioAv↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2135- TQ,    Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets
- in-vitro, Nor, HaCaT
*HO-1↑, *NRF2↑, *e-ERK↑, *e-Akt↑, *AMPKα↑, *ROS⇅, *eff↓, *tumCV∅,

Showing Research Papers: 251 to 300 of 322
Prev Page 6 of 7 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 322

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↑, 1,   antiOx↑, 3,   ATF3↑, 1,   CYP1A1↓, 1,   Fenton↑, 2,   Ferroptosis↑, 2,   GPx4↓, 2,   GSH↓, 5,   GSH↑, 2,   HO-1↑, 1,   Iron↑, 1,   lipid-P↓, 3,   NRF2↑, 1,   ROS?, 1,   ROS↓, 6,   ROS↑, 15,   ROS⇅, 1,   TrxR↓, 1,   TrxR1↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1,   IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   EGF↓, 1,   MEK↓, 3,   p‑MEK↓, 2,   MMP↓, 10,   Raf↓, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   p‑AMPK↑, 1,   cMyc↓, 3,   FASN↑, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   ac‑Histones↑, 1,   HK2↓, 1,   lactateProd↓, 1,   PDK1↓, 1,   PKM2↓, 2,   SIRT1↓, 1,   SIRT1↑, 1,   SIRT2↑, 1,   SREBP1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 10,   Akt∅, 1,   p‑Akt↓, 4,   p‑Akt↑, 1,   APAF1↑, 1,   Apoptosis↓, 2,   Apoptosis↑, 15,   ATF2↓, 1,   Bak↑, 1,   BAX↑, 6,   Bax:Bcl2↑, 3,   Bcl-2↓, 13,   Bcl-2↑, 1,   Bcl-xL↓, 4,   BID↑, 1,   BIM↓, 1,   BIM↑, 1,   Casp↑, 4,   Casp12?, 1,   Casp3↑, 11,   proCasp3↓, 1,   proCasp3↑, 1,   Casp7↑, 1,   Casp9↓, 1,   Casp9↑, 9,   Cyt‑c↑, 3,   DR4↑, 1,   DR5↑, 1,   Ferroptosis↑, 2,   GranB↑, 1,   GRP58↓, 1,   GSDME↑, 1,   hTERT/TERT↓, 2,   IAP1↓, 1,   iNOS↓, 1,   JNK↑, 2,   p‑JNK↓, 1,   p‑JNK↑, 5,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 3,   Necroptosis↑, 2,   NOXA↑, 1,   p27↑, 2,   p38↓, 2,   p38↑, 4,   p‑p38↓, 2,   p‑p38↑, 3,   Perforin↑, 1,   Pyro↑, 1,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 5,   Telomerase↓, 3,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↑, 1,   HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   HATs↑, 2,   miR-21↓, 1,   p‑pRB↓, 1,   tumCV↓, 7,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 1,   eIF2α↑, 1,   ER Stress↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

BNIP3↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   DNMT1↓, 1,   DNMTs↓, 2,   P53↑, 4,   P53∅, 1,   cl‑PARP↑, 8,   PCNA↓, 4,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   P21↑, 4,   RB1↑, 1,   TumCCA↓, 2,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD24↓, 1,   CD44↓, 2,   cMYB↓, 2,   CSCs↓, 3,   EMT↓, 5,   ERK↓, 18,   ERK↑, 4,   ERK∅, 1,   p‑ERK↓, 11,   p‑ERK↑, 3,   e-ERK↑, 1,   FOXO3↑, 2,   FOXO4↑, 1,   HDAC↓, 4,   HDAC1↓, 1,   HH↓, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   mTOR↓, 3,   NOTCH↓, 1,   NOTCH1↓, 1,   PI3K↓, 7,   PTEN↑, 1,   RAS↓, 1,   Src↓, 1,   STAT3↓, 6,   STAT5↓, 1,   TumCG↓, 8,   Wnt↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

Akt2↓, 1,   AP-1↓, 3,   AP-1↑, 1,   CA↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   mt-Ca+2↑, 1,   CD31↓, 1,   E-cadherin↑, 4,   EphB4↓, 1,   FAK↓, 3,   ITGB1↓, 1,   Ki-67↓, 1,   miR-155↓, 1,   miR-203↑, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 8,   MMP9↓, 13,   MMPs↓, 2,   N-cadherin↓, 2,   PDGF↓, 1,   RIP3↓, 1,   RIP3↑, 1,   Slug↓, 1,   TGF-β↓, 2,   TumCI↓, 7,   TumCMig↓, 10,   TumCP↓, 10,   TumCP∅, 1,   TumMeta↓, 4,   Twist↓, 1,   uPA↓, 2,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   EGFR↓, 4,   p‑EGFR↓, 2,   EGR1↑, 1,   Hif1a↓, 9,   LOX1↓, 1,   TAMS↝, 1,   VEGF↓, 8,   VEGFR2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

NHE1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 9,   CXCR4↓, 3,   IFN-γ↓, 1,   IFN-γ↑, 3,   IKKα↑, 1,   IL1↓, 2,   IL10↓, 1,   IL1β↓, 3,   IL2↑, 2,   IL4↑, 1,   IL6↓, 2,   IL6↑, 1,   Inflam↓, 6,   p‑IκB↓, 1,   JAK2↓, 1,   MDSCs↓, 1,   NF-kB↓, 13,   NK cell↑, 1,   p50↓, 1,   p65↓, 2,   PD-L1↓, 1,   PGE2↓, 3,   PSA↓, 2,   T-Cell↑, 1,   TLR1↑, 1,   TLR2↑, 1,   TLR4↑, 1,   TNF-α↓, 3,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 6,   BioAv↑, 2,   chemoR↓, 1,   ChemoSen↑, 4,   Dose↝, 5,   eff↓, 7,   eff↑, 12,   eff↝, 2,   Half-Life↓, 2,   Half-Life↝, 4,   MDR1↓, 1,   RadioS↑, 3,   selectivity↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AR↓, 1,   AST↓, 1,   EGFR↓, 4,   p‑EGFR↓, 2,   EZH2↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 2,   IL6↑, 1,   Ki-67↓, 1,   PD-L1↓, 1,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↓, 1,   chemoP↑, 6,   ChemoSideEff↓, 3,   hepatoP↑, 5,   neuroP↑, 2,   radioP↑, 2,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 2,  
Total Targets: 272

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 5,   Catalase↑, 3,   GSH↑, 5,   GSTs↑, 1,   H2O2↑, 1,   HO-1↑, 4,   lipid-P?, 1,   lipid-P↓, 2,   MDA↓, 2,   MPO↓, 1,   NRF2↑, 4,   RNS↓, 1,   ROS↓, 9,   ROS⇅, 1,   SOD↑, 5,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 2,   CREB↑, 2,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   e-Akt↑, 1,   Apoptosis↓, 1,   iNOS↓, 2,   JNK↓, 2,   p‑JNK↓, 1,   MAPK↓, 3,   necrosis↓, 1,   p38↓, 2,   p‑p38↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   tumCV∅, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 5,   ERK↑, 2,   p‑ERK↓, 4,   p‑ERK↑, 1,   e-ERK↑, 1,   FOXO1↝, 1,   HDAC↓, 1,   HDAC2↓, 1,   PI3K↑, 1,   PTEN↑, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   p‑Cofilin↓, 1,   Rho↓, 1,   ROCK1↓, 1,   p‑Smad1↑, 1,   SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD5↑, 1,   TIMP1↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   eNOS↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB?, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   ICAM-1↓, 1,   IFN-γ↓, 1,   p‑IKKα↓, 2,   IL1β↓, 3,   IL4↓, 1,   IL6↓, 2,   IL8↓, 2,   Inflam↓, 6,   NF-kB↓, 4,   p‑NF-kB↓, 1,   p‑p50↓, 1,   p‑p65↓, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BChE↓, 1,   BDNF↑, 2,   tau↓, 1,   TrkB↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   Aβ↑, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   eff↓, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BMD↑, 1,   EGFR↓, 1,   GutMicro↑, 1,   IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 3,   CardioT↓, 1,   cognitive↑, 3,   hepatoP↑, 3,   memory↑, 3,   neuroP↑, 4,   Strength↑, 1,   toxicity↓, 1,   toxicity∅, 2,  
Total Targets: 103

Scientific Paper Hit Count for: ERK, ERK signaling
16 Berberine
16 Curcumin
14 Quercetin
13 Sulforaphane (mainly Broccoli)
12 Silymarin (Milk Thistle) silibinin
11 Shikonin
10 EGCG (Epigallocatechin Gallate)
10 Fisetin
10 Magnetic Fields
9 Apigenin (mainly Parsley)
9 Thymoquinone
8 Baicalein
7 Artemisinin
7 Caffeic acid
6 Luteolin
6 Propolis -bee glue
6 Honokiol
6 Lycopene
5 Alpha-Lipoic-Acid
5 Chrysin
5 Piperine
5 Resveratrol
4 Silver-NanoParticles
4 Allicin (mainly Garlic)
4 Radiotherapy/Radiation
4 Astaxanthin
4 Carvacrol
4 Emodin
4 Rosmarinic acid
4 Vitamin K2
3 Cisplatin
3 Berbamine
3 Boswellia (frankincense)
3 Chlorogenic acid
3 Ferulic acid
3 Garcinol
3 Phenethyl isothiocyanate
3 Piperlongumine
3 Ursolic acid
3 Vitamin C (Ascorbic Acid)
2 Andrographis
2 Ashwagandha(Withaferin A)
2 beta-glucans
2 Beta-Caryophyllene
2 Betulinic acid
2 Bromelain
2 Boron
2 Zinc
2 Capsaicin
2 Thymol-Thymus vulgaris
2 Crocetin
2 Cucurbitacin
2 Deguelin
2 Dandelion Root
2 Paclitaxel
2 Gambogic Acid
2 Geraniol
2 Magnetic Field Rotating
2 Myricetin
2 Nimbolide
2 Phenylbutyrate
2 Pterostilbene
2 Sanguinarine
2 Salvia miltiorrhiza
2 Urolithin
1 1,8-Cineole
1 Camptothecin
1 alpha Linolenic acid
1 Anethole/trans-Anethole
1 Ascorbyl Palmitate
1 Trastuzumab
1 Baicalin
1 Biochanin A
1 Bacopa monnieri
1 brusatol
1 α-Bisabolol / Chamomile oil
1 Centella asiatica / Gotu kola → asiaticoside
1 Chlorophyllin
1 Cinnamon
1 Citric Acid
1 Coenzyme Q10
1 Vitamin E
1 Copper and Cu NanoParticles
1 Dihydrocaffeic Acid
1 gefitinib, erlotinib
1 Photodynamic Therapy
1 Bicalutamide
1 Docosahexaenoic Acid
1 Dipyridamole
1 Ellagic acid
1 eicosapentaenoic acid
1 Fucoidan
1 flavonoids
1 Gallic acid
1 Ginseng
1 Graviola
1 Grapeseed extract
1 Hydrogen Gas
1 Huperzine A/Huperzia serrata
1 Magnolol
1 Methyl salicylate / Sweet Birch oil
1 Naringin
1 Niclosamide (Niclocide)
1 Oleocanthal
1 Oxygen, Hyperbaric
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Plumbagin
1 Kaempferol
1 Salvia officinalis
1 Aromatherapy
1 Aflavin-3,3′-digallate
1 Tomatine
1 Turmerones
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:105  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page